Novo Nordisk Demerger Expected To Aid External Collaborations
Novo expects the demerger of its healthcare and enzyme businesses in January 2001 to enhance possibilities for collaborations with other companies.
You may also be interested in...
Novo pays $25 million up front for a pre-clinical IL-21 antibody and global IP rights to blocking IL-21.
Novo Nordisk's hemophilia treatment NovoSeven (recombinant Factor VIIa) generated U.S. sales of approximately $19 mil. in its first three months on the U.S. market, Novo indicated in an Aug. 11 statement on half-year financial results. Novo began marketing the product in the U.S. in April.
Novo Nordisk's diabetes mellitus treatment insulin aspart has an onset of action time of 10 to 20 minutes, according to European draft labeling for the human insulin analogue.